PROGRESS WHO granted prequalification for QUINVAXEM® in cPAD, a fully liquid pentavalent vaccine with a demonstrated immunogenicity and safety profile, in an innovative, compact, prefilled, auto-disable (cPAD) injection system; our TB medicine is included in World Health Organization (WHO) interim policy guidance on the treatment of MDR-TB issued in June 2013.